Dan Chen
Partner Genesis BioCapital
A pioneer in the field of cancer immunotherapy and protein engineering and co-author of the Cancer Immunity Cycle, Dr. Chen is an experienced physician-scientist, key opinion leader, drug developer, and entrepreneur. Dr. Chen spent over a decade at Genentech, as Vice President and Global Head of Cancer Immunotherapy Development, where he focused on development of immune modulatory, anti-angiogenic, and ADCs as targeted therapies and their accompanying diagnostic tools. This included leading clinical development for atezolizumab (TECENTRIQ), the first approved PD-L1 inhibitor, from pre-IND to clinical trials and commercialization. Dr. Chen then joined IGM Biosciences as Chief Medical Officer, developing novel engineered multivalent and multispecific therapeutics and overseeing the company’s growth from a small 25-person team to one of the most successful IPOs of 2019. He is also a founding partner of Genesis BioCapital and founder and CEO of Synthetic Design Lab.
Seminars
- Understanding the different avenues of innovation of masked and conditionally active ADCs to highlight ability to reduce on-target, off-tumor toxicity
- Breaking down the principles and advantages of bispecific ADC logic gates including AND gate EGFR-cMET ADCs
- Analyzing the maturing pipeline of multispecific ADCs to set the context of how antibody-led ADC innovation will translate to the clinic
Round up the conversation from the Discovery Biology presentations in a closing panel discussion with the speakers. Make sure to come with your questions prepared as the presenters explore the risk and rationale for pursuing novel ADC targets, and the potential of bispecific ADCs to enhance tumor targeting and therapeutic index compared to traditional ADCs.
